Abstract
Inhibitory receptors of the CD28 family, CTLA-4 and PD-1 deliver negative signals that regulate the balance between T cell activation, tolerance, and immunopathology. Manipulation of these pathways has been utilized by pathogens and tumors to establish chronic infections or to promote tumor survival. In this review, we examine the role of CTLA-4 and PD-1 in regulating immune response and discuss their therapeutic potential during aging.
Keywords: Inhibitory, T cell, CTLA-4, PD-1
Current Pharmaceutical Design
Title: The Use of the Inhibitory Receptors for Modulating the Immune Responses
Volume: 14 Issue: 26
Author(s): S. M. Henson, R. Macaulay, S. Kiani-Alikhan and A. N. Akbar
Affiliation:
Keywords: Inhibitory, T cell, CTLA-4, PD-1
Abstract: Inhibitory receptors of the CD28 family, CTLA-4 and PD-1 deliver negative signals that regulate the balance between T cell activation, tolerance, and immunopathology. Manipulation of these pathways has been utilized by pathogens and tumors to establish chronic infections or to promote tumor survival. In this review, we examine the role of CTLA-4 and PD-1 in regulating immune response and discuss their therapeutic potential during aging.
Export Options
About this article
Cite this article as:
Henson M. S., Macaulay R., Kiani-Alikhan S. and Akbar N. A., The Use of the Inhibitory Receptors for Modulating the Immune Responses, Current Pharmaceutical Design 2008; 14 (26) . https://dx.doi.org/10.2174/138161208786264124
DOI https://dx.doi.org/10.2174/138161208786264124 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lessons from Nature: Sources and Strategies for Developing AMPK Activators for Cancer Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry Nitroimidazole Radiopharmaceuticals in Hypoxia: Part II Cytotoxicity and Radiosensitization Applications
Current Radiopharmaceuticals Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients
Current Clinical Pharmacology Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology Breast Cancer Stem Cells and Intrinsic Subtypes: Controversies Rage On
Current Stem Cell Research & Therapy Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Angiogenesis New Targets for the Development of Anticancer Chemotherapies
Current Pharmaceutical Design Clinical Applicability of Conditioning Techniques in Ischemia-Reperfusion Injury: A Review of the Literature
Current Cardiology Reviews Antiangiogenesis and Radiotherapy: What Is the Role of Combined Modality Treatment?
Current Medicinal Chemistry - Anti-Cancer Agents Age and Dose-Dependent Effects of Alpha-Lipoic Acid on Human Microtubule- Associated Protein Tau-Induced Endoplasmic Reticulum Unfolded Protein Response: Implications for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Encountering and Advancing Through Antiangiogenesis Therapy for Gliomas
Current Pharmaceutical Design The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry